PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Activity
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
PPARGC1A rs8192678 polymorphism
Steatosis
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Jul 2021
07 Jul 2021
Historique:
received:
08
02
2021
revised:
08
04
2021
accepted:
20
04
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
31
7
2021
Statut:
ppublish
Résumé
The association between PPARGC1A rs8192678 and nonalcoholic fatty liver disease (NAFLD) requires further confirmation. In addition, it is still unknown whether PPARGC1A rs8192678 is associated with hepatic histological features in NAFLD in the Chinese population. To investigate the interaction between PPARGC1A rs8192678 and nonalcoholic steatohepatitis (NASH), and whether this polymorphism is associated with hepatic histological features. Fifty-nine patients with liver biopsy-proven NAFLD and 93 healthy controls were recruited to a cohort representing the Chinese Han population. The SAF (steatosis, activity, and fibrosis) scoring system was used for hepatic histopathological evaluation. The polymorphisms of PPARGC1A rs8192678 and patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 were genotyped. The intrahepatic mRNA expression of PPARGC1A was evaluated by real-time polymerase chain reaction. Thirty-seven patients with NAFLD had NASH, of which 12 were nonobese. The PPARGC1A rs8192678 risk A allele (carrying GA and AA genotypes) had the lowest The PPARGC1A rs8192678 risk A allele is associated with NAFLD, and with S2-3, A ≥ 2 and NASH in NAFLD patients, independent of PNPLA3 rs738409, and may be associated with nonobese NASH.
Sections du résumé
BACKGROUND
BACKGROUND
The association between PPARGC1A rs8192678 and nonalcoholic fatty liver disease (NAFLD) requires further confirmation. In addition, it is still unknown whether PPARGC1A rs8192678 is associated with hepatic histological features in NAFLD in the Chinese population.
AIM
OBJECTIVE
To investigate the interaction between PPARGC1A rs8192678 and nonalcoholic steatohepatitis (NASH), and whether this polymorphism is associated with hepatic histological features.
METHODS
METHODS
Fifty-nine patients with liver biopsy-proven NAFLD and 93 healthy controls were recruited to a cohort representing the Chinese Han population. The SAF (steatosis, activity, and fibrosis) scoring system was used for hepatic histopathological evaluation. The polymorphisms of PPARGC1A rs8192678 and patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 were genotyped. The intrahepatic mRNA expression of PPARGC1A was evaluated by real-time polymerase chain reaction.
RESULTS
RESULTS
Thirty-seven patients with NAFLD had NASH, of which 12 were nonobese. The PPARGC1A rs8192678 risk A allele (carrying GA and AA genotypes) had the lowest
CONCLUSION
CONCLUSIONS
The PPARGC1A rs8192678 risk A allele is associated with NAFLD, and with S2-3, A ≥ 2 and NASH in NAFLD patients, independent of PNPLA3 rs738409, and may be associated with nonobese NASH.
Identifiants
pubmed: 34321850
doi: 10.3748/wjg.v27.i25.3863
pmc: PMC8291025
doi:
Substances chimiques
Membrane Proteins
0
PPARGC1A protein, human
0
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
0
Lipase
EC 3.1.1.3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3863-3876Informations de copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare that there is no conflict of interest related to this study.
Références
Hepatology. 2017 Dec;66(6):1885-1893
pubmed: 28741298
Liver Int. 2008 Mar;28(3):385-92
pubmed: 17999673
Diabetes. 2011 Aug;60(8):2051-60
pubmed: 21677280
Clin Exp Pharmacol Physiol. 2008 Oct;35(10):1172-7
pubmed: 18565194
Am J Clin Nutr. 2013 Feb;97(2):326-31
pubmed: 23269818
Am J Physiol Endocrinol Metab. 2014 Jan 15;306(2):E157-67
pubmed: 24280126
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485
pubmed: 27581063
J Gastroenterol Hepatol. 2010 Apr;25(4):772-7
pubmed: 20492333
Gastroenterology. 2017 Jan;152(1):243-256
pubmed: 27658772
Metabolism. 2010 Apr;59(4):581-6
pubmed: 19913841
Hepatol Int. 2019 Nov;13(6):766-776
pubmed: 31559605
Diabetes. 2003 Mar;52(3):895-8
pubmed: 12606537
Ann Hum Genet. 2014 Jan;78(1):23-32
pubmed: 24359475
J Clin Pharmacol. 2010 Sep;50(9):1022-30
pubmed: 20498286
Turk J Med Sci. 2019 Aug 08;49(4):1089-1094
pubmed: 31390852
Biomed Res Int. 2015;2015:285491
pubmed: 26185753
Am J Gastroenterol. 2009 Apr;104(4):861-7
pubmed: 19293782
J Gastroenterol Hepatol. 2012 Sep;27(9):1520-7
pubmed: 22414273
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
Acta Biochim Biophys Sin (Shanghai). 2011 Apr;43(4):248-57
pubmed: 21325336
Diabet Med. 2005 Nov;22(11):1516-21
pubmed: 16241916
BMC Med Genomics. 2018 Jun 20;11(1):54
pubmed: 29925367
Biochem Pharmacol. 2011 Dec 15;82(12):2008-15
pubmed: 21933665
Diabetes Res Clin Pract. 2008 Nov;82(2):190-6
pubmed: 18823672
Biochem Biophys Res Commun. 2003 Feb 7;301(2):578-82
pubmed: 12565902
Stroke. 2006 Sep;37(9):2260-5
pubmed: 16902166
Int J Obes (Lond). 2012 Mar;36(3):363-8
pubmed: 21894159
J Dig Dis. 2011 Feb;12(1):38-44
pubmed: 21276207
BMC Gastroenterol. 2008 Jun 27;8:27
pubmed: 18588668
Hepatology. 2010 Feb;51(2):454-62
pubmed: 20101745
J Clin Gastroenterol. 2020 Apr;54(4):378-387
pubmed: 31651571
Medicine (Baltimore). 2016 Mar;95(12):e3120
pubmed: 27015186